Table 2.
Comparison of clinical characteristics of ENR and LNR patients in the purely regional recurrence group.
| Characteristic | Total | ENR group | LNR group | P-value |
|---|---|---|---|---|
| (n = 325)% | (n = 183)% | (n = 142)% | ||
| Age (years) | 0.094 | |||
| ≤46 years | 175 (53.8) | 106 (57.9) | 69 (48.6) | |
| >46 years | 150 (46.2) | 77 (42.1) | 73 (51.4) | |
| Gender | 0.567 | |||
| Male | 261 (80.3) | 149 (81.4) | 112 (78.9) | |
| Female | 64 (19.7) | 34 (18.6) | 30 (21.1) | |
| Smoking status | 0.165 | |||
| Non-smoker | 192 (59.1) | 102 (55.7) | 90 (63.4) | |
| Smoker | 133 (40.9) | 81 (44.3) | 52 (36.6) | |
| Alcohol abuse | 0.420 | |||
| Non-drinker | 266 (81.8) | 147 (80.3) | 119 (83.8) | |
| Drinker | 59 (18.2) | 36 (19.7) | 23 (16.2) | |
| Tumor family history | 0.796 | |||
| No | 229 (70.5) | 130 (71.0) | 99 (69.7) | |
| Yes | 96 (29.5) | 53 (29.0) | 43 (30.3) | |
| Cranial nerve symptom | 0.936 | |||
| N0 | 304 (93.5) | 171 (93.4) | 133 (93.7) | |
| Yes | 21 (6.5) | 12 (6.6) | 9 (6.3) | |
| Baseline value of EBV-DNA | 0.009 | |||
| ≤2,000 | 84 (25.8) | 37 (20.2) | 47 (33.1) | |
| >2,000 | 241 (74.2) | 146 (79.8) | 95 (66.9) | |
| Histological type | 0.183 | |||
| WHO I/II | 12 (3.7) | 9 (4.9) | 3 (2.1) | |
| WHO III | 313 (96.3) | 174 (95.1) | 139 (97.9) | |
| T stage | 0.337 | |||
| 1/2 | 117 (36.0) | 70 (38.3) | 47 (33.1) | |
| 3/4 | 208 (64.0) | 113 (61.7) | 95 (66.9) | |
| N stage | 0.157 | |||
| 0/1 | 139 (42.8) | 72 (39.3) | 67 (47.2) | |
| 2/3 | 186 (57.2) | 111 (60.7) | 75 (52.8) | |
| TNM stage | 0.606 | |||
| I/II | 59 (18.2) | 35 (19.1) | 24 (16.9) | |
| III/IV | 266 (81.8) | 148 (80.9) | 118 (83.1) | |
| Induction chemotherapy | 0.077 | |||
| No | 111 (34.2) | 55 (30.1) | 56 (39.4) | |
| Yes | 214 (65.8) | 128 (69.9) | 86 (60.6) | |
| Concurrent chemotherapy | 0.625 | |||
| No | 47 (14.5) | 28 (15.3) | 19 (13.4) | |
| Yes | 278 (85.5) | 155 (84.7) | 123 (86.6) | |
| Adjuvant chemotherapy | 0.113 | |||
| No | 295 (90.8) | 162 (88.5) | 133 (93.7) | |
| Yes | 30 (9.2) | 21 (11.5) | 9 (6.3) | |
| Post-recurrence treatment options | 0.689 | |||
| BST | 17 (5.2) | 9 (4.9) | 8 (5.6) | |
| Salvage surgery | 162 (49.9) | 94 (51.4) | 68 (47.9) | |
| Re-irradiation | 64 (19.7) | 32 (17.5) | 32 (22.5) | |
| Chemotherapy | 82 (25.2) | 48 (26.2) | 34 (24.0) | |